Physician profile
Ericka Green
NPI 1275110900
$3,878.84
in general payments reported to CMS, 2019-2025
20 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $1,117 · 2023: $590 · 2024: $642 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,141.10 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $750.61 | 2021-2025 | Caplyta |
| Alkermes, INC. | $359.17 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $283.89 | 2025 | Auvelity |
| Indivior INC. | $187.49 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $181.05 | 2024-2025 | Fanapt |
| Orexo US, INC. | $169.36 | 2022-2023 | Zubsolv |
| Gilead Sciences, INC. | $163.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $155.39 | 2024-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $136.31 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $134.45 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $63.83 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $30.81 | 2023 | Ingrezza |
| Braeburn INC. | $21.00 | 2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $20.78 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.56 | 2025 | |
| Ardelyx, INC. | $16.31 | 2024 | Ibsrela |
| Scilex Pharmaceuticals INC. | $16.12 | 2022 | |
| Lilly USA, LLC | $15.00 | 2021 | |
| Viiv Healthcare Company | $13.26 | 2023 | Dovato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.